Citations

Clear

904 citation(s) found for "Gordon, S".

Reflections on meta-analyses involving trials stopped early for benefit: Is there a problem and if so, what is it?
Bassler, Dirk , Montori, Víctor M. , Briel, Matthias , Glasziou, Paul , Walter, Stephen D. , Ramsay, Tim , Guyatt, Gordon , Montori, Victor M

Mayo Clinic

Statistical Methods in Medical Research | December 15, 2011 | Volume: 22 | Issue: 2 | Pages: 159-168

10.1177/0962280211432211 | PMID 22170891 Get It

We review controversies associated with randomized controlled trials (RCTs) stopped early for apparent benefit (truncated RCTs or tRCTs) and present our groups’ perspective. Long-established theory, simulations and recent empirical evidence demonstrate that tRCTs will on average overestimate treatment effects, and this overestimation may be large, particularly when tRCTs have small number of events. Theoretical considerations and simulations demonstrate that on average, meta-analyses of RCTs with appropriate stopping rules will lead to only trivial overestimation of treatment effects. However, tRCTs will disproportionally contribute to meta-analytic estimates when tRCTs occur early in the sequence of trials with few subsequent studies, publication of nontruncated RCTs is delayed, there is publication bias, or tRCTs result in a ‘freezing’ effect in which ‘correcting’ trials are never undertaken. To avoid applying overestimates of effect to clinical decision-making, clinicians should view the results of individual tRCTs with small sample sizes and small number of events with skepticism. Pooled effects from meta-analyses including tRCTs are likely to overestimate effect when there is a substantial difference in effect estimates between the tRCTs and the nontruncated RCTs, and in which the tRCTs have a substantial weight in the meta-analysis despite themselves having a relatively small number of events. Such circumstances call for sensitivity analyses omitting tRCTs.
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997
Smith, Mitchell R. , Flinn, Ian W. , Grever, Michael R. , Rowe, Jacob M. , Dewald, Gordon W., Bennett, John M. , Paietta, Elisabeth , Byrd, John C., Hussein, Mohamad A., Appelbaum, Frederick R. , Larson, Richard A. , Litzow, Mark R. , Tallman, Martin S. , Byrd, John C. , Neuberg, Donna , Lazarus, Hillard M. , Larson, Richard A , Flinn, Ian W , Byrd, John C

Mayo Clinic

Blood | July 30, 2011 | Volume: 118 | Issue: 13 | Pages: 3525-3527

10.1182/blood-2011-03-342485 | PMID 21803850 Get It

Abstract Chemotherapy-related myeloid neoplasia (t-MN) is a significant late toxicity concern after cancer therapy. In the randomized intergroup phase 3 E2997 trial, initial therapy of chronic lymphocytic leukemia with fludarabine plus cyclophosphamide (FC) compared with fludarabine alone yielded higher complete and overall response rates and longer progression-free, but not overall, survival. Here, we report t-MN incidence in 278 patients enrolled in E2997 with a median 6.4-year follow-up. Thirteen cases (4.7%) of t-MN occurred at a median of 5 years from initial therapy for chronic lymphocytic leukemia, 9 after FC and 4 after fludarabine alone. By cumulative incidence methodology, rates of t-MN at 7 years were 8.2% after FC and 4.6% after fludarabine alone (P = .09). Seven of the 9 cases of t-MN after FC occurred without additional therapy. Abnormalities involving chromosomes 5 or 7 were found in 10 cases, which suggests alkylator involvement. These data suggest that FC may induce more t-MN than fludarabine alone.
Long-term outcome of patients undergoing surgical repair of isolated pulmonary valve stenosis. Follow-up at 20-30 years.
Kopecky, Steven L., McGoon, Michael D., Mair, D D , Porter, Co-burn J., Ilstrup, D M, McGoon, Dwight C., Kirklin, John W., Danielson, Gordon K., Gersh, Bernard J.

Mayo Clinic

Circulation | June 17, 2011 | Volume: 78 | Issue: 5 | Pages: 1150-1156

10.1161/01.cir.78.5.1150 | PMID 3180374 Get It

In a group of 191 consecutive patients who underwent operation at the Mayo Clinic for isolated pulmonary valve stenosis between 1956 and 1967, late results were excellent. In patients surviving operation before the age of 21 years, long-term survival was similar to that in an age- and sex-matched control population. In the other patients, late survival and functional status were good, but survival was poorer than in the control population. This late attrition, most likely due to the sequelae of long-standing right ventricular hypertrophy, suggests the need for continued surveillance. Late sudden death occurred in only three patients, between 10 and 21 years postoperatively. The finding of normal life expectancy for such patients who survive operation before age 21 is important for actuarial purposes and for the patients' career and employment plans.
RETRACTED: Foxp3-positive macrophages display immunosuppressive properties and promote tumor growth
Manrique, Soraya Zorro, Mirza, Noweeda, Stein‐Streilein, Joan, Gordon, Siamon , Lustgarten, Joseph, Duque‐Correa, Maria A. , Hoelzinger, Dominique B. , Dominguez, Ana Lucía , Lin, Hsi‐Hsien

Mayo Clinic

Journal of Experimental Medicine | June 14, 2011 | Volume: 208 | Issue: 7 | Pages: 1485-1499

10.1084/jem.20100730 | PMID 21670203 Get It

Regulatory T cells (T reg cells) are characterized by the expression of the forkhead lineage-specific transcription factor Foxp3, and their main function is to suppress T cells. While evaluating T reg cells, we identified a population of Foxp3-positive cells that were CD11b+F4/80+CD68+, indicating macrophage origin. These cells were observed in spleen, lymph nodes, bone marrow, thymus, liver, and other tissues of naive animals. To characterize this subpopulation of macrophages, we devised a strategy to purify CD11b+F4/80+Foxp3+ macrophages using Foxp3-GFP mice. Analysis of CD11b+F4/80+Foxp3+ macrophage function indicated that these cells inhibited the proliferation of T cells, whereas Foxp3− macrophages did not. Suppression of T cell proliferation was mediated through soluble factors. Foxp3− macrophages acquired Foxp3 expression after activation, which conferred inhibitory properties that were indistinguishable from natural Foxp3+ macrophages. The cytokine and transcriptional profiles of Foxp3+ macrophages were distinct from those of Foxp3− macrophages, indicating that these cells have different biological functions. Functional in vivo analyses indicated that CD11b+F4/80+Foxp3+ macrophages are important in tumor promotion and the induction of T reg cell conversion. For the first time, these studies demonstrate the existence of a distinct subpopulation of naturally occurring macrophage regulatory cells in which expression of Foxp3 correlates with suppressive function.
Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin
Fernández, Hugo F. , Sun, Zhuoxin , Litzow, Mark R. , Luger, Selina M. , Paietta, Elisabeth , Racevskis, Janis, Dewald, Gordon W., Ketterling, Rhett P. , Rowe, Jacob M. , Tallman, Martin S. , Lazarus, Hillard M. , Ketterling, Rhett P

Mayo Clinic

Blood | March 18, 2011 | Volume: 117 | Issue: 20 | Pages: 5306-5313

10.1182/blood-2010-09-309229 | PMID 21415269 Get It

AbstractWe report the results of a prospective, randomized phase 3 trial evaluating the use of gemtuzumab ozogamicin (GO) in an intensive consolidation approach in 657 patients 17-60 years of age. Patients in first complete remission (CR1) after cytarabine and standard- or high-dose daunorubicin induction received 2 cycles of consolidation with high-dose cytarabine followed by peripheral blood progenitor cell collection. The 352 patients who entered consolidation were randomized to receive GO (n = 132) or not (n = 138) and then proceeded to autologous hematopoietic cell transplantation (HCT). GO was given to 67 patients. Median follow-up was 50.9 months. Results of the intention-to-treat analysis demonstrated a 4-year disease-free survival (DFS) of 33.6% versus 35.9% (P = .54) and an overall survival (OS) of 41.3% versus 41.9% (P = .52) for those randomized to receive GO versus no GO, respectively. Patients with favorable- and intermediate-risk acute myeloid leukemia (AML) treated with high-dose daunorubicin and autologous HCT had 4-year DFS rates of 60% and 40% and OS rates of 80% and 49.3%, respectively. For younger AML patients in CR1, autologous HCT should be considered in favorable- and intermediate-cytogenetic risk patients who do not have an allogeneic donor. The addition of a single dose of GO in this setting did not improve outcomes. This trial is registered at http://www.clinicaltrials.gov as NCT00049517.
Abstract 2145: Identification of genomic alterations and integrated gene expression profiles for MSS colon tumors
Loo, Lenora W. M. , Tiirikainen, Maarit , Okimoto, Gordon , Lum‐Jones, Annette, Seifried, Ann, Gallinger, Steven , Thibodeau, Steven, Cheng, Iona C. , Casey, Graham , Marchand, Loı̈c Le

Mayo Clinic

Cancer Research | February 25, 2011 | Volume: 70 | Issue: 8_Supplement | Pages: 2145-2145

10.1158/1538-7445.am10-2145 Get It

Abstract Colon cancer is the result of a multi-step process involving the accumulation of genetic and epigenetic alterations leading to the transformation of normal colon epithelium to adenocarcinoma. Identification of characteristic genetic alterations is of critical importance to increase our understanding of the transformation process. We focused our analysis on the most common molecular sub-type of colon cancers, microsatellite stable (MSS) and CpG island methylator phenotype (CIMP)-negative, to identify characteristic copy number alteration (CNA) events and associated gene expression profiles using high-resolution genome-wide microarrays. DNA and RNA were extracted from 41 fresh-frozen paired colon tumors and adjacent normal tissue collected by the Colon Cancer Family Registry. Genomic profiles, such as CNAs and loss of heterozygosity (LOH), were identified with the Affymetrix Genome-Wide Human SNP 6.0 array for both tumor and adjacent normal tissue. Gene expression profiles of tumors and adjacent normal tissue were identified with the Affymetrix GeneChip Human Exon 1.0 ST array. Partek Genomics Suite software was used for analysis and data integration. We identified recurrent (>25%) CNAs in several chromosomal regions: gain in 1q, 7p, 7q, 8q, 13q, 20p, 20q, Xp, Xq and loss in 5q, 8p, 14q, 16p, 17p, 18p, and 18q. In addition, based on the allele information from the SNP arrays, we found a subset of these recurrent CNAs were associated with LOH. Preliminary results from the integration of CNA and gene expression data in tumors indicate that a subset of these recurrent CNAs is associated with the disruption of gene expression. For example, we observed recurrent copy number gain in 8q24.21, the genomic region containing the c-MYC gene, and associated up-regulation of c-MYC gene expression in tumors compared to adjacent normal tissue. In another example, recurrent copy number loss at 5q22.2 was associated with down-regulation of APC gene expression; loss of function of this tumor suppressor is associated with both hereditary and sporadic colon cancer. This genome-wide characterization of both genomic alterations and gene expression may help identify key genes and pathways that are disrupted in this common molecular subtype of colon cancer. We will present detailed results from this integrated and comprehensive genetic profiling of MSS and CIMP-negative colon cancers. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2145.
The Triad of Gastric Leiomyosarcoma, Functioning Extra-Adrenal Paraganglioma and Pulmonary Chondroma
Carney, J A, Sheps, Sheldon G., Go, V. L. W., Gordon, Hymie, Gordon, Hymie

Mayo Clinic

New England Journal of Medicine | July 28, 2010 | Volume: 296 | Issue: 26 | Pages: 1517-1518

10.1056/nejm197706302962609 | PMID 865533 Get It

Relative Risk Estimated from the Ratio of Two Median Unbiased Estimates
Carter, Rickey E. , Lin, Yan , Lipsitz, Stuart R. , Hermayer, Kathie L., Newcombe, Robert Gordon , Carter, Rickey E

Mayo Clinic

Journal of the Royal Statistical Society Series C: Applied Statistics | June 10, 2010 | Volume: 59 | Issue: 4 | Pages: 657-671

10.1111/j.1467-9876.2010.00711.x | PMID 20711511 Get It

SummaryClinical trials often include binary end points. In some cases, no successes are observed and the usual large sample estimates of relative risk are undefined. The paper proposes an estimator for relative risk based on the median unbiased estimator. The relative risk estimator proposed is well defined and performs satisfactorily for a wide range of data configurations. To facilitate the use of the estimator, a deterministic bootstrap confidence interval is also proposed, and an SAS macro is available to perform the necessary calculations. An on-going randomized clinical trial motivated the development of the estimator and is used to illustrate the approach.
Beyond Mortality: Future Clinical Research in Acute Lung Injury
Spragg, Roger G., Bernard, Gordon R. , Checkley, William , Gajić, Ognjen, Hall, Jesse B., Israel, Elliott, Jain, Manu , Needham, Dale M. , Randolph, Adrienne G. , Rubenfeld, Gordon D., Schoenfeld, David , Ware, Lorraine B. , Young, Duncan , Harabin, Andrea L., Curtis, J. Randall , Guyatt, Gordon , Thompson, Bruce , Randolph, Adrienne G

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | March 11, 2010 | Volume: 181 | Issue: 10 | Pages: 1121-1127

10.1164/rccm.201001-0024ws | PMID 20224063 Get It

Abstract Mortality in National Heart, Lung and Blood Institute–sponsored clinical trials of treatments for acute lung injury (ALI) has decreased dramatically during the past two decades. As a consequence, design of such trials based on a mortality outcome requires ever-increasing numbers of patients. Recognizing that advances in clinical trial design might be applicable to these trials and might allow trials with fewer patients, the National Heart, Lung and Blood Institute convened a workshop of extramural experts from several disciplines. The workshop assessed the current state of clinical research addressing ALI, identified research needs, and recommended: (1) continued performance of trials evaluating treatments of patients with ALI; (2) development of strategies to perform ALI prevention trials; (3) observational studies of patients without ALI undergoing prolonged mechanical ventilation; and (4) development of a standardized format for reporting methods, endpoints, and results of ALI trials.